CoChat

Infliximab improves health-related quality of life in the presence of comorbidities among patients with moderate-to-severe psoriasis

Feldman, S.R., Gottlieb, A.B., Bala, M., Wu, Y., Eisenberg, D., Guzzo, C., Li, S., Dooley, L.T., Menter, A. · 2008 · British Journal of Dermatology
Cited by 86

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Psoriasis affects patients both physically and psychologically. OBJECTIVES: To investigate the effect of comorbidities on health-related quality of life (HRQoL) and to determine whether infliximab improved HRQoL in the presence of these conditions. METHODS: In this multicentre, double-blind study, 835 patients with moderate-to-severe plaque psoriasis were randomized to receive infliximab 3 or 5 mg kg(-1) or placebo at weeks 0, 2 and 6. Infliximab-treated patients were re-randomized at week 14 to receive the same treatment every 8 weeks or as needed through week 46; placebo patients crossed over to infliximab 5 mg kg(-1) at week 16. Disease severity (Psoriasis Area and Severity Index, PASI) and HRQoL (Dermatology Life Quality Index, DLQI; 36-item Short-Form Health Survey, SF-36) were measured at various time points. The effect of patient comorbidities on baseline HRQoL was assessed using multiple regression models. The impact of key comorbidities on infliximab treatment effect was also assessed. RESULTS: Disease severity (PASI), depression and psoriatic arthritis (PsA) were predictors of poor baseline HRQoL. At week 10, infliximab 3 and 5 mg kg(-1) significantly improved physical and mental health dimensions of the SF-36 and the DLQI (all P < 0.001). Consistent improvement in HRQoL with infliximab treatment was observed regardless of baseline patient characteristics or comorbidities. Through week 50, HRQoL and PASI scores were most improved with infliximab 5 mg kg(-1) administered every 8 weeks. CONCLUSIONS: Disease severity, depression and PsA were significant predictors of poor HRQoL. Infliximab significantly improved HRQoL, regardless of these characteristics.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2133.2008.08727.x

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 86

Metadata

Authors
Feldman, S. R., Gottlieb, A. B., Bala, M., Wu, Y., Eisenberg, D., Guzzo, C., Li, S., Dooley, L. T., & Menter, A.
Venue
British Journal of Dermatology
Published
2008-09
Volume
159
Issue
3
Pages
704-710
ISSN
  • 0007-0963 (ISSN-L)
  • 1365-2133
OpenAlex
W2080459647
Cited by
86
References
3
FWCI
2.18
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Infliximab improves health-related quality of life in the presence of comorbidities among patients with moderate-to-severe psoriasis. https://app.cochat.ai/papers/10.1111/j.1365-2133.2008.08727.x
The paper
Feldman, S. R., Gottlieb, A. B., Bala, M., Wu, Y., Eisenberg, D., Guzzo, C., Li, S., Dooley, L. T., & Menter, A. (2008). Infliximab improves health-related quality of life in the presence of comorbidities among patients with moderate-to-severe psoriasis. British Journal of Dermatology. https://doi.org/10.1111/j.1365-2133.2008.08727.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.